Biogen (BIIB) Acquisitions (2010 - 2024)
Biogen (BIIB) recorded quarterly Acquisitions of -$1.1 billion in Q4 2024, down 282.02% quarter-over-quarter from $590.5 million in Q4 2023, and down 282.02% on a YoY basis from $590.5 million in Q1 2024.
Biogen (BIIB) Acquisitions (2010 - 2024) Analysis & Trends
Biogen's Acquisitions history runs 6 years deep, the most recent figure standing at -$1.1 billion for Q4 2024.
- In Q4 2024, Acquisitions fell 282.02% year-over-year to -$1.1 billion; the TTM figure through Dec 2025 stood at -$484.3 million (changed 0.0% YoY), while the FY2023 annual figure was $6.9 billion, changed N/A from the prior year.
- Acquisitions was -$1.1 billion for Q4 2024 at Biogen, down from $590.5 million in the prior quarter.
- In the past five years, Acquisitions ranged from a high of $590.5 million in Q4 2023 to a low of -$1.1 billion in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -1.89 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 8.78 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 109.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 65.00 Mn |
| 10 | Biogen | 28.75 Bn | 24.47 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.07 Bn |
| Dec 31, 2023 | 590.50 Mn |
| Mar 31, 2015 | 198.80 Mn |
| Mar 31, 2012 | 72.40 Mn |
| Dec 31, 2011 | 5.00 Mn |
| Dec 31, 2010 | 32.50 Mn |
| Mar 31, 2010 | 39.98 Mn |